Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes — Stella

Home/Type2diabetes/A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes

View on ClinicalTrials.gov

Recruiting

Back to Type2diabetes trials

A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(2 sites)

China

China-Japan Friendship Hospital, Beijing, Beijing Municipality

China-Japan Friendship Hospital, Beijing, Beijing Municipality

Key details

Phase

Post-approval study

Sponsor

Hua Medicine Limited

Collaborators

Shanghai Branch, KunTuo Medical Research and Development (Beijing) Co., Ltd.

Enrollment target

~2,000 participants

Started

December 2023

Primary completion

April 2026

Age range

18 Years and older

Last updated February 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.